602 related articles for article (PubMed ID: 10928310)
1. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Strain EC; Stoller K; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
[TBL] [Abstract][Full Text] [Related]
2. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.
Duke AN; Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2010 Aug; 211(3):303-12. PubMed ID: 20577717
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
5. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
[TBL] [Abstract][Full Text] [Related]
6. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
Rosado J; Walsh SL; Bigelow GE; Strain EC
Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
[TBL] [Abstract][Full Text] [Related]
7. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
9. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
[TBL] [Abstract][Full Text] [Related]
13. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.
Wesson DR
J Psychoactive Drugs; 2004 May; Suppl 2():119-28. PubMed ID: 15279124
[TBL] [Abstract][Full Text] [Related]
17. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
[No Abstract] [Full Text] [Related]
18. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
[TBL] [Abstract][Full Text] [Related]
19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.
Soyka M
Expert Opin Drug Deliv; 2015 Feb; 12(2):339-47. PubMed ID: 25156759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
